The Person

Senior officer · Board member · AI leader

Uri
Yablonka

20+ years in biopharma spanning journalism, entrepreneurship, operations, and strategic communications. Senior executive at a publicly traded clinical-stage ALS biotech. Building autonomous AI agent systems that run entire biopharma functions — because the future of drug development is not more headcount, it is better architecture.

The Background

Career & Focus

A career at the intersection of science, communication, and AI

Executive Leadership

Senior officer and board member at publicly traded biotech. C-suite experience spanning operations, investor relations, corporate communications, and strategic development.

AI Builder

Designing and deploying autonomous agent systems that handle R&D workflows, CMC documentation, regulatory submissions, and IR functions at scale.

Journalist & Writer

Began career in science journalism. That foundation — rigorous research, clear writing, asking hard questions — informs everything written here.

Community Builder

26,000+ followers across LinkedIn, X, and Bluesky. Building a community of biopharma professionals navigating the AI transition.

ALS Focus

Deep expertise in ALS competitive intelligence, pipeline analysis, and the rapidly evolving therapeutic landscape for amyotrophic lateral sclerosis.

Governance

Advising boards and audit committees on AI governance frameworks, SOX compliance for autonomous systems, and responsible AI deployment in public companies.

Topics Covered

Agentic AI in R&D

Autonomous systems running drug discovery, target validation, and compound optimization workflows end-to-end.

AI Governance

SOX compliance, board oversight frameworks, and audit committee guidance for public biotech companies deploying AI agents.

Regulatory AI

Generative AI in FDA and EMA regulatory submissions — accelerating approvals and improving the quality of regulatory documents.